BioPharma Resources

Drug Trial Radar · NCT07272434

Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Adults Aged 60 Aears and Above

Last checked: Nov 19, 2026Latest source record: Dec 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 25,000 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

25,000

Planned (sponsor's estimate)

Start

Oct 22, 2025

Primary completion

Jul 31, 2026

Study completion Dec 31, 2028

Sponsor

Sponsor type
Industry
Collaborators
Henan Center for Disease Control and Prevention; Hunan Provincial Center for Disease Control and Prevention; Hubei Provincial Center for Disease Control and Prevention; Shaanxi Provincial Center for Disease Control and Prevention; Guangdong Center for Disease Prevention and Control; Shandong Province Centers for Disease Control and Prevention; Sichuan Center for Disease Control and Prevention; Hebei CDC ,China
First posted
Dec 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults≥ 60 years of following a single dose of the RSV vaccine(CHO cell) vaccine .This study will also assess if the vaccine is safe and induces an immune response.

Conditions

  • Respiratory Syncytial Virus (RSV)

Interventions

  • Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)Biological

    0.5 mL per dose

  • Placebo (Saline solution)Biological

    0.5 mL per dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The first-time incidence rate per person-year of Lower Respiratory Tract Disease (LRTD).Time frame: From 14 days after vaccination until the end of the first RSV epidemic season,assessed up to 12 months.

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Guangdong Provincial Center for Disease Control and Prevention

    Guangzhou, Guangdong, China · Not yet recruiting

  • Hebei Provincial Center for Disease Control and Prevention

    Shijiazhuang, Hebei, China · Active not recruiting

  • Henan Center for Disease Control and Prevention

    Zhengzhou, Henan, China · Recruiting

  • Hubei Provincial Center for Disease Control and Prevention

    Wuhan, Hubei, China · Recruiting

  • Hunan Provincial Center for Disease Control and Prevention

    Changsha, Hunan, China · Recruiting

  • Shaanxi Provincial Center for Disease Control and Prevention

    Xi'an, Shaanxi, China · Recruiting

  • Shandong Province Centers for Disease Control and Prevention

    Jinan, Shandong, China · Active not recruiting

  • Sichuan Center for Disease Control and Prevention

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.